Evaluation of surface contamination in a hospital hematology-oncology pharmacy

Journal of Oncology Pharmacy Practice

Volumn 15, Issue 1, 2009, Pages 53-61

  Touzin, Karine ^a   Bussieres, Jean François ^a   Langlois, Éric ^b   Lefebvre, Michel ^b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

Author keywords

Cyclophosphamide; Environmental contamination; Hazardous drugs; Ifosfamide; Methotrexate; Monitoring; Pharmacy; Quantification; Sampling

Indexed keywords

CYCLOPHOSPHAMIDE; IFOSFAMIDE; METHOTREXATE;

ARTICLE; CONCENTRATION (PARAMETERS); CONTAMINATION; ENVIRONMENTAL MONITORING; HEMATOLOGY; HOSPITAL HYGIENE; HOSPITAL PHARMACY; ONCOLOGY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ANTINEOPLASTIC AGENTS; CYCLOPHOSPHAMIDE; DRUG COMPOUNDING; ENVIRONMENTAL MONITORING; EQUIPMENT CONTAMINATION; HUMANS; IFOSFAMIDE; METHOTREXATE; OCCUPATIONAL EXPOSURE; PHARMACY SERVICE, HOSPITAL;

EID: 61749100798     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155208096904     Document Type: Article

References (41)

1. Turci R., Sottani C., Spagnoli G., Minoia C. Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: A review of analytical methods. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 789 (2): 169-209.
2. Acampora A., Castiglia L., Miraglia N. et al. A case study: Surface contamination of cyclophosphamide due to working practices and cleaning procedures in two Italian hospitals. Ann Occup Hyg 2005; 49 (7): 611-618.
3. Minoia C., Turci R., Sottani C., Schiavi A., Perbellini L., Angeleri S., Draicchio F., Apostoli P. Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide. Rapid Commun Mass Spectrom 1998; 12 (20): 1485-93.
4. Nygren O. Wipe sampling as a tool for monitoring aerosol deposition in workplaces. J Environ Monit 2006; 8 (1): 49-52.
5. Sabatini L., Barbieri A., Tosi M., Violante FS A new high-performance liquid chromatographic/electrospray ionization tandem mass spectrometric method for the simultaneous determination of cyclophosphamide, methotrexate and 5-fluorouracil as markers of surface contamination for occupational exposure monitoring. J Mass Spectrom 2005; 40 (5): 669-74.
6. Mason HJ, Blair S., Sams C. et al. Exposure to antineoplastic drugs in two UK hospital pharmacy units. Ann Occup Hyg 2005; 49 (7): 603-10.
7. Sessink PJ, Anzion RB, Van den Broek PH, Bos RP Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Weekbl Sci 1992; 14 (1): 16-22.
8. Connor TH, Sessink PJ, Harrison BR, Pretty JR, Peters BG, Alfaro RM et al. Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: Results of three studies. Am J Health Syst Pharm 2005; 62 (5): 475-84.
9. Sessink PJ, Boer KA, Scheefhals AP, Anzion RB, Bos RP Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health 1992; 64 (2): 105-12.
10. Schulz H., Bigelow S., Dobish R., Chambers C. Antineoplastic agent workplace contamination study: The Alberta Cancer Board Pharmacy perspective. J Oncol Pharm Practice 2005; 11: 101-09.
11. Sessink PJ, Wittenhorst BC, Anzion RB, Bos RP Exposure of pharmacy technicians to antineoplastic agents: Reevaluation after additional protective measures. Arch Environ Health 1997; 52 (3): 240-44.
12. Connor TH, Anderson RW, Sessink PJ, Broadfield L., Power LA Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am J Health Syst Pharm 1999; 56 (14): 1427-32.
13. The United States Pharmacopeial Convention. Pharmaceutical compounding - sterile preparations. Chapter 797, Rockville, 2003.
14. National Institute for Occupational Safety and Health. NIOSH Alert. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings. http://www.cdc.gov/niosh/docs/2004-165/ pdfs/2004-165.pdf (Accessed 12 October 2005).
15. American Society of Health-System Pharmacists. Guidelines on hazardous drugs. Am J Health-Syst Pharm 2006; 63: 1172-93.
16. Gallant C., Bussières JF, Plante R., Bertrand G., Léonard M., Goyer N. et al. Guide de prévention - Manipulation sécuritaire des médicaments dangereux - ASSTSAS, Montréal, QC. ISBN-978-289618-015-8, 2008, 158 pages.
17. Bussières J., Sessink PJ, Prot-Labarthe S., Larocque D. Évaluation de l'exposition professionnelle aux antinéoplasiques dans une unité de pharmacie hospitalière. Archives des Maladies Professionnelles 2006; 67 (6): 880-88.
18. Larson RR, Khazaeli MB, Dillon HK Monitoring method for surface contamination caused by selected antineoplastic agents. Am J Health Syst Pharm 2002; 59 (3): 270-77.
19. Vandenbroucke J., Robays H. How to protect environment and employees against cytotoxic agents, the UZ Ghent experience. J Oncol Pharm Practice 2001; 6: 146-52.
20. Schmaus G., Schierl R., Funck S. Monitoring surface contamination by antineoplastic drug using gas chromatography-mass spectrometry and voltametry. Am J Health Sys Pharm 2002; 59: 956-61.
21. Crauste-Manciet S., Sessink PJ, Ferrari S., Jomier JY, Brossard D. Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators. Ann Occup Hyg 2005; 49 (7): 619-28.
22. Hedmer M., Tinnerberg H., Axmon A., Jönsson BA Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital. Int Arch Occup Environ Health 2007; 81 (7): 899-911.
23. Harrison BR, Peters BG, Bing MR Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques. Am J Health Syst Pharm 2006; 63 (18): 1736-44.
24. Wick C., Slawson MH, Jorgenson JA, Tyler LS Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Heath Syst Pharm 2003; 60: 2314-20.
25. Spivey S., Connor TH Determination of sources of workplace contamination with antineoplastic drugs and comparison of conventional IV drug preparation versus a closed system. Hosp Pharm 2003; 38: 135-39.
26. Ros JJ, Simons KA, Verzul JM et al. Practical applications of a validated method of analysis for the detection of traces of cyclophosphamide on injection bottles and at oncological outpatient center. Ziekenhuisfarmacie 1997; 13: 168-71; (In Dutch).
27. Hepp R., Gentschew G. External contamination of commercially available cytotoxic drugs. Krankenhauspharmazie 1998; 19: 22-7; (In German).
28. Paul H., Baumann L., Artelt S. et al. Umgebungskontrolle auf contamination mit zytostatika: Nachweis von platin auf oberflächen in räumlicheiten mit zentraler ytostatikaherstelling. Krankenhauspharmazie 1998; 4: 181-86.
29. Delporte JP, Chenoix P., Hubert PH Chemical contamination of the primary packaging of 5-fluorouracil RTU solutions commercially available on the Belgian market. Eur Hosp Pharm 1999; 5: 119-21.
30. Nygren O., Gustavsson B., Ström L. et al. Cisplatin contamination observed on the outside of drug vials. Ann Occup Hyg 2002; 46: 555-57.
31. Favier B., Gilles L., Ardiet C. et al. External contamination of vials containing cytotoxic agents supplied by pharmaceutical manufacturers. J Oncol Pharm Pract 2003; 9: 15-20.
32. Mason HJ, Morton J., Garfitt SJ et al. Cytotoxic drug contamination on the outside of vials delivered to a hospital pharmacy. Ann Occup Hyg 2003; 47: 681-5.
33. Funck von S., Schierl R. Sicherheit bei der zytostatikahersatellung. Dtsch Apoth Ztg 2004; 10: 1089-94.
34. Wilken A. Boebachtungen zur auβenkontamination der primärvpackungen von zytostatika. Krankenhauspharmazie 1997; 1: 37-39.
35. Bussières JF, Théorêt Y., Prot-Labarthe S., Larocque D. A one year pilot study to monitor surface contamination by hazardous drugs in a hemato-oncology pharmacy satellite. Am J Health-Syst Pharm 2007; 64: 531-35.
36. Connor TH, Anderson RW, Sessink PJ, Spivey SM Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area. Am J Health Syst Pharm 2002; 59: 68-72.
37. Sessink PJM, Rolf M-AE, Ryden NS Evaluation of the PhaSeal hazardous drug containment system. Hosp Pharm 1999; 34: 1311-17.
38. Tans B., Willems I. Comparative contamiantion study with cyclophosphamide, fluouracil and ifosfamide standard technique versus a proprietary closed-handling system. J Oncol Pharm Pract 2004; 10: 217-23.
39. Gustavsson B. Evaluation of a technetium assay for monitoring of occupational exposure to cytotoxic drugs. J Oncol Pharm Pract 1997; 3: 46.
40. Nygren O., Gustavsson B., Strom L., Eriksson R., Jarneborn L., Friberg A. Exposure to anti-cancer drugs preparation and administration. Investigations of an open and closed system. J Environ Monit 2002; 4: 739-42.
41. United States Pharmacopeia (USP). USP Guidebook to Pharmaceutical Compounding-Sterile Preparations, Chapter 797, http://www.usp.org/ products/797Guidebook/visited on June 17